Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2024.

IF 1.6 Q3 Medicine

Communicable diseases intelligence (2018) Pub Date : 2025-07-30 DOI:10.33321/cdi.2025.49.039

Monica M Lahra, Tiffany R Hogan

引用次数: 0

Abstract

Abstract: Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

查看原文本刊更多论文

澳大利亚脑膜炎球菌监测：报告期为2024年10月1日至12月31日。

摘要：季度报告中的数据仅限于按辖区和血清组描述IMD病例数，并在2024年扩大到包括头孢曲松、青霉素、环丙沙星和利福平的抗微生物药物耐药性数据。AMSP年度报告中载有对每个历年实验室确认的IMD的全面分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊